X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203880
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-december-13-2023-38736.pdf
https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/novartis-issues-voluntary-us-nationwide-recall-two-lots-sandimmuner-oral-solution-cyclosporine-oral
https://www.prnewswire.com/news-releases/novartis-issues-voluntary-us-nationwide-recall-of-two-lots-of-sandimmune-oral-solution-cyclosporine-oral-solution-usp-100-mgml-due-to-crystallization-301996335.html
https://www.prnewswire.com/news-releases/cequa-cyclosporine-ophthalmic-solution-0-09-phase-4-data-showed-sustained-improvement-in-dry-eye-disease-signs-and-symptoms-in-patients-switched-from-restasis-cyclosporine-ophthalmic-emulsion-0-05-301954006.html
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-september-27-2023-3225.pdf
https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/novartis-issues-voluntary-nationwide-recall-one-lot-sandimmuner-oral-solution-cyclosporine-oral
https://www.prnewswire.com/news-releases/novartis-issues-voluntary-nationwide-recall-of-one-lot-of-sandimmune-oral-solution-cyclosporine-oral-solution-usp-100-mgml-due-to-crystallization-301923365.html
https://www.accessdata.fda.gov/scripts/ires/index.cfm?action=print.getPrintData&ts=11202310416
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207606
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-october-5-2022-44974.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216046
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-april-13-2022-1649826529.pdf
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-cyclosporine-1646027861.pdf
https://www.fiercepharma.com/pharma/abbvie-s-blockbuster-eye-drug-restasis-under-threat-as-fda-approves-viatris-copycat
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205894
https://finance.yahoo.com/news/ocular-therapeutix-announces-topline-results-120000746.html
https://www.hsa.gov.sg/announcements/product-recall/recall-of-one-batch-of-ikervis-1mg-ml-eye-drop-emulsion
https://www.unither-pharma.com/actualites/nouveau-dans-le-rejet-de-greffe-de-cornee-lansm-delivre-une-autorisation-pour-le-premier-collyre-industriel-a-base-de-ciclosporine-2/
https://www.unither-pharma.com/en/news/new-in-corneal-transplant-rejection-the-ansm-issues-an-authorisation-for-the-first-industrial-eye-drop-based-on-ciclosporin-2/
https://www.prnewswire.com/news-releases/santen-announces-us-fda-filing-acceptance-of-new-drug-application-nda-for-cyclosporine-topical-ophthalmic-emulsion-0-1-for-the-treatment-of-severe-vernal-keratoconjunctivitis-in-patients-ages-4-18--301159476.html
https://www.prnewswire.com/news-releases/novartis-pharmaceuticals-corporation-corrective-action-for-certain-blister-packages-of-sandimmune-and-neoral-100-mg-soft-gelatin-capsules-in-the-us-due-to-failure-to-meet-child-resistant-packaging-requirements-301026437.html
https://www.prnewswire.com/news-releases/lilly-and-incyte-announce-top-line-results-from-phase-3-study-breeze-ad4-of-oral-selective-jak-inhibitor-baricitinib-in-combination-with-topical-corticosteroids-in-patients-with-moderate-to-severe-atopic-dermatitis-not-controlle-300993285.html
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/sun-pharma-launches-cequa-to-treat-dry-eye-disease-in-us/articleshow/71578198.cms
https://www.fiercepharma.com/pharma/both-a-history-for-anticompetitive-conduct-abbvie-and-allergan-should-get-close-scrutiny-at
https://www.fiercepharma.com/pharma/abbvie-s-il-23-hopeful-skyrizi-scores-nod-from-england-s-cost-watchdog?utm_source=internal&utm_medium=rss
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210721
https://endpts.com/aldeyras-eye-drug-stumbles-in-pivotal-test-in-patients-with-rare-inflammatory-disease/
https://endpts.com/scotus-just-turn-its-back-on-allergans-legal-maneuver-to-take-a-blow-at-inter-partes-review-what-did-you-expect/
https://www.fiercepharma.com/pharma/supreme-court-sends-allergan-packing-over-tribal-licensing-gambit
https://www.fiercebiotech.com/sponsored/mitotech-a-dry-eye-treatment-aimed-at-mitochondria
https://www.reuters.com/article/us-allergan-results/botox-maker-allergans-revenue-forecast-misses-estimates-shares-drop-idUSKCN1PN1F4
https://www.fiercebiotech.com/biotech/aurinia-posts-mixed-midphase-data-would-be-restasis-rival?mkt_tok=eyJpIjoiWkRNelpETXlaR016TWpRMyIsInQiOiJwWTRBRWRVcUtUOUVcL1pPVHhcL1wvdXFydFVpMUppMmZncTZ2eHlOQVwvUFBidEROY2pmdENGVW5rdjdJOGwrMDVnRXZPUHArZ0dMV2tTMXhhRHJWQXBZSkpMUndxYUUxNlFIcnJaS0E0ZjJGVCtIS3lHeU5VK3JFUzVJY0NoMWtrQUoifQ%3D%3D&mrkid=67302085&utm_medium=nl&utm_source=internal
https://endpts.com/allergan-and-its-mohawk-allies-pitch-their-sovereign-immunity-case-to-scotus-and-the-timing-couldnt-be-worse/
https://www.biopharmadive.com/news/allergan-mohawk-tribe-restasis-supreme-court-patent-case/546180/?utm_source=Sailthru&utm_medium=email&utm_campaign=Issue:%202019-01-16%20BioPharma%20Dive%20%5Bissue:18961%5D&utm_term=BioPharma%20Dive
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-january-9-2019-1547012578.pdf
Market Place
Share 
